Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Market Insight - What Obama's victory means for pharma

This article was originally published in Scrip

Executive Summary

The new US President who takes the oath of office on January 20th, 2009 is committed to changing substantially the way the country delivers heathcare. That would have been true regardless of who won the election, but Barack Obama will focus much more attention on elements meant to curb pharma profits than John McCain would have. An October analysis by the Boston Consulting Group pegs the pharma revenue decline from Obama's proposals at at least $10 billion a year – and perhaps as much as three times that amount. Moreover, the election results in two ways give the new President extra clout in pushing his health system reform ideas: his Democratic party made significant gains in both houses of Congress (because of recounts and run-off elections, the final numbers won't be known until December) and the enthusiasm he generated – with the largest voter turnout in US history – gives him a mandate to make big changes.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts